IP Library Granted Patent US 11,419,916
Granted Patent B2
US 11,419,916 · App. 15/120,850 · Granted Aug 23, 2022

Methods and compositions for inducing differentiation of human brown adipocyte progenitors

Inventor: Olivier D. Boss (Boston, MA)
Assignee: ENERGESIS PHARMACEUTICALS, INC.
A61K38/1825A61K31/165A61K31/166A61K31/353A61K31/426A61K31/44A61K31/4745A61K31/506A61K31/5415A61K31/5575A61K38/105A61K38/185A61K38/195A61K38/204A61K38/22A61K38/2278
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,419,916
App. No.
15/120,850
Granted
Aug 23, 2022
Kind
B2
Abstract

This disclosure relates to compositions and methods for recruiting brown adipocytes in vitro and in vivo from brown adipocyte progenitor cells found in human skeletal muscle. Methods for treating metabolic disease are also provided. Additionally, methods for treating hypothermia are provided. In some embodiments, the brown adipocyte recruiter is a human protein or peptide. In other embodiments the brown adipocyte recruiter may be a non-human protein or peptide. In still other embodiments, the brown adipocyte recruiter is a small molecule or natural product.

Claims (9)

1. A method of promoting brown adipogenesis in a subject in need thereof, the method comprising:

contacting a cell of a subject having a metabolic disorder with an agent selected from one or more of:

fibroblast growth factor (FGF) 7 (FGF7); and

stromal cell-derived factor 1 (SDF-1); and

transplanting said cell into the subject after said contacting step;

wherein the cell is a BAT progenitor cell isolated from human skeletal muscle;

wherein the metabolic disorder is selected from the group consisting of obesity, type II diabetes, insulin resistance, hyperinsulinemia, hypertension, hyperlipidemia, hepatosteatosis, fatty liver, non-alcoholic fatty liver disease, hyperuricemia, polycystic ovarian syndrome, acanthosis nigricans, hyperphagia, triglyceride storage disease, Bardet-Biedl syndrome, Laurence-Moon syndrome, Prader-Willi syndrome, neurodegenerative diseases, and/or Alzheimer's disease.

2. The method of claim 1 wherein the cell is positive for CD34.

3. The method of claim 1 wherein the cell is negative for CD31.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2018
From: BOSS, OLIVIER D.
To: ENERGESIS PHARMACEUTICALS, INC.
Reel/Frame 046910/0962 →
CONFIRMATORY LICENSE Recorded Sep 19, 2016
From: ENERGESIS PHARMACEUTICALS, INC
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040069/0076 →
Continuity (2)
Provisional Application 61966496 · Feb 24, 2014
Related Publication 20160361386A1 · Dec 15, 2016